Go to PegaPoll
PEGAPOLL · NEWS

Pancreatic Cancer Pill Hailed as Biggest Treatment Breakthrough in Decades

Guardian Wellness · 2026-11-20
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

Daraxonrasib, an experimental pill targeting KRAS mutations that drive most pancreatic cancers, has produced unusually strong results in a trial involving 61 people with newly diagnosed advanced disease that had spread to other organs. Tumours stopped growing in 90% of participants, while just over 60% saw their tumours shrink or disappear. In about 8% of patients, cancer became undetectable on CT scans.

After one year of treatment, 76.6% of participants were still alive, compared with the usual 40–45% one-year survival rate for patients receiving chemotherapy alone. Participants were followed for an average of 18 months, and some remained free of detectable returning cancer during that period. However, researchers do not yet know how long the benefits will last, and doctors stress that the drug cannot currently be considered a cure.

The results were presented in Barcelona by Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who described the findings as the closest he had seen to complete remission in metastatic pancreatic cancer. The disease remains among the deadliest common cancers: half of newly diagnosed patients die within three months, and only about 3% of those whose cancer has spread survive five years. Cancer Research UK chief executive Michelle Mitchell called the results the biggest advance in decades, but said further trials are needed before the treatment can be considered for NHS use.

Continue in the app — vote & join in ➔
Source: Guardian Wellness · via ahirlevel.hu

Related news